You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Quetiapine and Rivastigmine Not Often Helpful for Agitation in Alzheimer's Disease

  • Authors: News Author: Laurie Barclay, MD
    CME Author: Charles Vega, MD, FAAFP
  • CME Released: 2/22/2005
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 2/22/2006
Start Activity


Target Audience and Goal Statement

This article is intended for primary care physicians, geriatricians, psychiatrists, neurologists, and other specialists who care for patients with dementia.

The goal of this activity is to provide the latest medical news to physicians and other healthcare professionals in order to enhance patient care.

Upon completion of this activity, participants will be able to:

  • Identify predictors of rapid cognitive decline in patients with dementia.
  • Describe the efficacy of quetiapine and rivastigmine in outcomes of behavior and cognition among patients with severe dementia.


Disclosures

As an organization accredited by the ACCME, Medscape requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as "financial relationships in any amount, occurring within the past 12 months, that create a conflict of interest."

Medscape encourages Authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Laurie Barclay, MD

    Laurie Barclay is a freelance reviewer and writer for Medscape.

    Disclosures

    Disclosure: Dr. Barclay has reported no significant financial interests.

Reviewer(s)

  • Gary Vogin, MD

    Senior Medical Editor, Medscape

    Disclosures

    Disclosure: Dr. Vogin has reported no significant financial interests.

CME Author(s)

  • Charles P Vega, MD

    Associate Professor; Residency Director, Department of Family Medicine, University of California, Irvine

    Disclosures

    Disclosure: Dr. Vega has disclosed that he has received grants for educational activities from Pfizer.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape designates this educational activity for 0.25 category 1 credit(s) toward the AMA Physician's Recognition Award. Each physician should claim only those credits that reflect the time he/she actually spent in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CME

Quetiapine and Rivastigmine Not Often Helpful for Agitation in Alzheimer's Disease

Authors: News Author: Laurie Barclay, MD CME Author: Charles Vega, MD, FAAFPFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME Released: 2/22/2005

Valid for credit through: 2/22/2006

processing....

Feb. 22, 2005 — Neither quetiapine nor rivastigmine help with agitation in Alzheimer's disease, and quetiapine is associated with greater decline in cognitive function than placebo, according to the results of a randomized study in the Feb. 17 Online First issue of the BMJ. The investigators recommend against using quetiapine in this setting.

"Antipsychotic drugs are commonly prescribed to many people with dementia (up to 45%) in residential or nursing homes, often for prolonged periods," write Clive Ballard, MD, from King's College in London, U.K., and colleagues. "Antipsychotics have modest efficacy but are commonly associated with substantial adverse effects such as parkinsonism, tardive dyskinesia, reduced quality of life, and cardiac arrhythmias. More seriously, an increased risk of stroke has been reported in patients taking the two most widely prescribed atypical antipsychotics, risperidone and olanzapine."

In this double-blind trial performed at health care facilities in northeast England, 93 patients with Alzheimer's Disease, dementia, and clinically significant agitation were randomized to receive quetiapine (an atypical antipsychotic), rivastigmine (a cholinesterase inhibitor), or placebo (double dummy). The primary outcome was the Cohen-Mansfield agitation inventory score at six weeks, and secondary outcomes were agitation at 26 weeks and cognition (severe impairment battery) at six and 26 weeks.

Of 80 patients (N = 93; 86%) who started treatment, 25 (31%) were randomized to rivastigmine, 26 (32%) to quetiapine, and 29 (36%) to placebo. Of 71 patients (N = 93; 89%) who tolerated the maximum protocol dose, 22 (31%) were assigned to rivastigmine, 23 (32%) to quetiapine, and 26 (37%) patients to placebo. Compared with placebo, neither quetiapine nor rivastigmine showed significant differences in improvement on the agitation inventory either at six or 26 weeks.

Of 50 patients who scored more than 10 on the severe impairment battery at baseline, 46 patients (82%) were included in the analysis at six-week follow-up, including 14 assigned to rivastigmine, 14 to quetiapine, and 18 to placebo. For quetiapine, the change in severe impairment battery score from baseline worsened vs placebo by an estimated average of -14.6 points (95% confidence interval [CI], -25.3 to -4.0) at six weeks ( P = .009) and -15.4 points (95% CI, -27.0 to -3.8) at 26 weeks ( P = .01). For rivastigmine, the corresponding changes were -3.5 points (95% CI, -13.1 to 6.2) lower at six weeks ( P = .5) and -7.5 points (95% CI, -21.0 to 6.0) lower at 26 weeks ( P = .30).

"Neither quetiapine nor rivastigmine are effective in the treatment of agitation in people with dementia in institutional care," the authors write. "Compared with placebo, quetiapine is associated with significantly greater cognitive decline."

Study limitations include modest sample size, multiple evaluations, and the substantial proportion of patients who were unable to complete the severe impairment battery.

"Given current concerns about the risk of stroke with risperidone and olanzapine, further studies are required to enable evidence-based pharmacological management of behavioural disturbance in dementia," the authors conclude. "Our results suggest that quetiapine should not be used as an alternative treatment to risperidone or olanzapine in people with dementia and highlight concerns regarding the long term use of antipsychotics in these patients."

The Alzheimer's Research Trust helped support this study, which was funded largely from general donations to Dr. Ballard's research and profits from previously completed commercially funded clinical trials. Dr. Ballard has received honoraria and research donations from AstraZeneca, maker of quetiapine, and Novartis, maker of rivastigmine.

BMJ. Posted online Feb. 17, 2005.